前沿速览002期| CAR-T治B淋 前沿览新知
01
一种新型自体CAR-T细胞疗法YTB323，在保存T细胞干性的同时，在临床前和早期临床开发中显示出增强的CAR-T细胞疗效
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
第一作者：Dickinson MJ
Cancer Discov (IF=28.2). 2023 Sep 6;13(9):1982-1997.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481129/
02
如何治疗由侵袭性淋巴瘤引起的继发中枢神经系统受累
How I treat secondary CNS involvement by aggressive lymphomas
第一作者：Alderuccio JP
Blood (IF=20.3). 2023 Sep 13:blood.2023020168.
全文网址：https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2023020168/497854/How-I-treat-secondary-CNS-involvement-by?redirectedFrom=fulltext
03
5' UTR的替代剪接限制了CD20 mRNA的翻译，并使靶向CD20免疫疗法产生耐药性
Alternative splicing of its 5' UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies
第一作者：Ang Z
Blood (IF=20.3). 2023 Sep 8:blood.2023020400.
全文网址：https://ashpublications.org/blood/article/doi/10.1182/blood.2023020400/497824/Alternative-splicing-of-its-5-UTR-limits-CD20-mRNA
04
对于侵袭性B细胞淋巴瘤的Axicabtagene ciloleucel治疗，苯达莫司汀清淋是氟达拉滨和环磷酰胺清淋方案的良好耐受性替代方案
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma
第一作者：Ong SY
Am J Hematol (IF=12.8). 2023 Sep 5.
全文网址：https://onlinelibrary.wiley.com/doi/10.1002/ajh.27069
05
在有细胞因子释放综合症和没有细胞因子释放综合症的患者中，CAR-T细胞疗法产生的结局相似
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
第一作者：Bhaskar ST
Blood Adv (IF=7.5). 2023 Sep 12;7(17):4765-4772.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468356/
06
宿主代谢组可预测由CAR-T细胞疗法引起的急性毒性的严重性和发病时间
Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy
第一作者：Jalota A
Blood Adv (IF=7.5). 2023 Sep 12;7(17):4690-4700.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468366/
07
CAR-T细胞疗法治疗大B细胞淋巴瘤后的非复发死亡率：来自DESCAR-T登记处的LYSA研究
Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry
第一作者：Lemoine J
Blood Adv (IF=7.5). 2023 Sep 6:bloodadvances.2023010624.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023010624/497767/Non-Relapse-Mortality-after-CAR-T-Cell-therapy-for
08
大B细胞淋巴瘤患者在CAR-T细胞疗法治疗失败后的结局
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas
第一作者：Dodero A
Br J Haematol (IF=6.5). 2023 Sep 10.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.19057
09
抗CD79b/CD3双特异性抗体与CAR19-T细胞联合用于B细胞淋巴瘤治疗
Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment
第一作者：Zheng WW
Cancer Immunol Immunother (IF=5.8). 2023 Sep 14.
全文网址：https://link.springer.com/article/10.1007/s00262-023-03526-z
10
CD4+ CAR-T细胞扩增与B细胞淋巴瘤患者的治疗缓解和治疗相关毒性有关
CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas
第一作者：Baur K
Bone Marrow Transplant (IF=4.8). 2023 Sep;58(9):1048-1050.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471494/
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2023.09-18 valid until 2025.09
供稿与审核：临床开发与医学部